Results 101 to 110 of about 32,913 (197)
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.ABSTRACT Background Tacrolimus is primarily metabolized by Cytochrome P450 (CYP)3A4/5. The Clinical Pharmacogenetics Implementation Consortium recommends increasing the initial dose 1.5‐ to 2‐fold in CYP3A5 expressers to enhance transplant outcomes. Our objective was to investigate the impact of CYP3A5 expresser status on tacrolimus dosing requirements
Yanting Wu +6 more
wiley +1 more source
British Journal of Haematology, Volume 208, Issue 3, Page 1084-1092, March 2026.Summary The efficacy of a triple combination of rabbit anti‐human thymocyte immunoglobulin (rATG), ciclosporin and eltrombopag (EPAG) was prospectively evaluated in patients with severe or transfusion‐dependent non‐severe aplastic anaemia (SAA) across 29 institutions in Japan. Sixty patients were enrolled, of whom 48 had SAA. The primary end‐point, the
Fumi Nakamura +17 more
wiley +1 more source
British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source
Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation
Clinical Transplantation, Volume 40, Issue 3, March 2026.ABSTRACT Introduction The anti‐CD52 monoclonal antibody alemtuzumab is used as an induction agent in kidney transplantation (KT) but remains understudied in septuagenarian recipients. The study purpose was to analyze the safety and efficacy of single‐dose alemtuzumab induction in septuagenarian deceased donor (DD) KT recipients.
David I. Harriman +6 more
wiley +1 more source
Diabetic Medicine, Volume 43, Issue 3, March 2026.Abstract Aims To explore UK key‐opinion leader perspectives on the future role of stem cell‐derived islets (sc‐islets) in islet transplantation for people with type 1 diabetes (T1D). Methods Four UK‐based key‐opinion leaders evaluated current limitations of donor islet transplantation and reviewed emerging evidence, clinical pathways and logistical ...
Thomas Strakosch, Shareen Forbes
wiley +1 more source
The FEBS Journal, Volume 293, Issue 5, Page 1358-1375, March 2026.Multimeric IgM‐fragment crystallizable region (Fc) fragments retain the ability to bind C1q and initiate the classical complement pathway, leading to C4 activation and deposition in vitro. However, the Fc cores can also inhibit complement‐dependent cytotoxicity by competing with surface‐bound antibodies for C1q engagement.
Andrea J. Pinto +9 more
wiley +1 more source
Immunology &Cell Biology, Volume 104, Issue 3, Page 276-311, March 2026.In this study, we used Foxp3‐fatemapping mice to examine the cell lineage stability of Treg cells in pregnancy. Ex‐Foxp3 cells were identified in gestational tissues. However, Treg cells retained lineage stability with no increased ex‐Foxp3 generation, regardless of inflammatory challenges that induce preterm birth.
Kerrie L Foyle +6 more
wiley +1 more source
Immunological Reviews, Volume 338, Issue 1, March 2026.ABSTRACT Sex plays a key role in shaping both anti‐cancer immunity and autoimmunity. Biological factors underlying sexual dimorphism have now been identified in multiple aspects of anti‐cancer immunity and autoimmunity. These factors include sex differences in hormone levels, chromosome complement, and expression of the long non‐coding RNA XIST.
Christian G. Bustillos +4 more
wiley +1 more source